Literature DB >> 12187466

Putative tests of frontal lobe function: a PET-study of brain activation during Stroop's Test and verbal fluency.

Barbara Ravnkilde1, Poul Videbech, Raben Rosenberg, Albert Gjedde, Anders Gade.   

Abstract

Stroop's test and the Verbal Fluency test are commonly argued to be measures of the integrity of the prefrontal cortex. This assumption has only to some degree been confirmed by lesion studies. In the present study, Positron Emission Tomography (PET) with H(2)(15)O was used to further validate Stroop's test and the Verbal Fluency as measures of frontal lobe function; both tests were implemented as activation paradigms during scanning of normal middleaged individuals. Stroop interference was found to activate the left anterior cingulate cortex, the supplementary motor cortex, thalamus, and the cerebellum. Although the prominent anterior cingulate activation is in the frontal lobe, it is not prefrontal. Verbal Fluency activated the left inferior frontal cortex and the left dorsolateral prefrontal cortex, the supplementary motor cortex, the anterior cingulate cortex and the cerebellum. These results bring this latter test closer to being a specific test of prefrontal function.

Mesh:

Year:  2002        PMID: 12187466     DOI: 10.1076/jcen.24.4.534.1033

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  21 in total

1.  Beyond consensus: Embracing heterogeneity in curated neuroimaging meta-analysis.

Authors:  Gia H Ngo; Simon B Eickhoff; Minh Nguyen; Gunes Sevinc; Peter T Fox; R Nathan Spreng; B T Thomas Yeo
Journal:  Neuroimage       Date:  2019-06-20       Impact factor: 6.556

2.  Interference resolution: insights from a meta-analysis of neuroimaging tasks.

Authors:  Derek Evan Nee; Tor D Wager; John Jonides
Journal:  Cogn Affect Behav Neurosci       Date:  2007-03       Impact factor: 3.282

3.  Activation of the caudal anterior cingulate cortex due to task-related interference in an auditory Stroop paradigm.

Authors:  Sven Haupt; Nikolai Axmacher; Michael X Cohen; Christian E Elger; Juergen Fell
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

Review 4.  Fibrofog and fibromyalgia: a narrative review and implications for clinical practice.

Authors:  Howard M Kravitz; Robert S Katz
Journal:  Rheumatol Int       Date:  2015-01-13       Impact factor: 2.631

Review 5.  Three key regions for supervisory attentional control: evidence from neuroimaging meta-analyses.

Authors:  Edna C Cieslik; Veronika I Mueller; Claudia R Eickhoff; Robert Langner; Simon B Eickhoff
Journal:  Neurosci Biobehav Rev       Date:  2014-11-11       Impact factor: 8.989

6.  Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment.

Authors:  Judy Pa; Adam Boxer; Linda L Chao; Adam Gazzaley; Katie Freeman; Joel Kramer; Bruce L Miller; Michael W Weiner; John Neuhaus; Julene K Johnson
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Alcohol attentional bias: drinking salience or cognitive impairment?

Authors:  Javad Salehi Fadardi; W Miles Cox
Journal:  Psychopharmacology (Berl)       Date:  2006-02-21       Impact factor: 4.530

Review 8.  Injury and recovery in the developing brain: evidence from functional MRI studies of prematurely born children.

Authors:  Laura R Ment; R Todd Constable
Journal:  Nat Clin Pract Neurol       Date:  2007-10

9.  Neurocognitive predictors of antidepressant clinical response.

Authors:  Gerard E Bruder; Jorge E Alvarenga; Daniel Alschuler; Karen Abraham; John G Keilp; David J Hellerstein; Jonathan W Stewart; Patrick J McGrath
Journal:  J Affect Disord       Date:  2014-05-04       Impact factor: 4.839

10.  Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.

Authors:  Gary W Small; Prabha Siddarth; Daniel H S Silverman; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Susan Y Bookheimer; S-C Huang; Jorge R Barrio; Michael E Phelps
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.